SHAREHOLDER ALERT: Weiss Law Reminds RMED, CYBE, LTRY, and MSTR Shareholders About Its Ongoing Investigations

NEW YORK, Sept. 16, 2022

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors Ra Medical Systems, Inc. (NYSE: RMED) in connection with the proposed merger of the Company with Catheter Precision, Inc. ("Catheter Precision").  The Merger is structured as a stock for stock reverse merger whereby all of Catheter Precision's outstanding convertible promissory notes and equity interests are to be exchanged for shares of RMED common stock and Catheter Precision options assumed by RMED.  Upon completion of the transaction, Catheter Precision shareholders are expected to own approximately 80% of the combined company, and RMED equity holders are expected to only own approximately 20% of the combined company.  If you own RMED shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/rmed

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CyberOptics Corporation (NASDAQ: CYBE) in connection with the proposed acquisition of CYBE by Nordson Corporation.  Under the terms of the merger agreement, CYBE shareholders will receive $54.00 in cash for each share of CYBE common stock owned.  If you own CYBE shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/cybe   

Weiss Law is investigating possible breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and certain Company officers of Lottery.com Inc. (NASDAQ: LTRY) relating to: (i) an admitted lack of adequate internal controls and procedures over financial reporting, including the failure to report entry into to a line of credit, failure to properly recognize revenue and the reporting of cash, and the inability to continue as a going concern; and (ii) noncompliance with state and federal laws governing the sale of lottery tickets.  .  If you own LTRY shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/ltry